Many Convoluted Stages Along AIID Patient Journeys The convoluted journey of patients with autoimmune and inflammatory diseases (AIIDs) has many stages. Each stage presents challenges that may cause patients to drop out before they get the care they need. Unlike cancer, diabetes, and heart disease, there are no population screening
Slow & Uncoordinated Path to Diagnosis & Treatment Today, autoimmune patient journeys are typically long, convoluted, and frustrating; from first awareness of symptoms to scheduling medical visits, diagnosis, treatment, and long-term care. Since many autoimmune & inflammatory diseases (AIIDs) emerge in youth or middle age and last a lifetime, the
Invisible Epidemic of Autoimmune Disease As we continue to illuminate the hidden costs of the long-ignored epidemic of autoimmune disease (AIID), we must shine a light on the highest autoimmune cost: Specialty pharmaceuticals. Current data largely underestimate total AIID costs, and accurate numbers are few and far between. Through our
A May 2022 NIH Report on autoimmune research makes clear why the AIID epidemic remains invisible & silent.
We are here republishing our 2014-17 Stanford MedX autoimmune presentations, plus unpublished material from our 2015 Autoimmune Workshop. As we develop our 2023 State of Autoimmunity Report, we’ve been revisiting our previous analyses. For another example, see our 2016-19 patient-centered vision and business opportunities post. In 2015, Bonnie conducted an
Back in 2019, pre-Covid pandemic, we already saw attractive investment & business opportunities to meet the large and growing need in autoimmune and chronic immuno-inflammatory diseases. Despite being as prevalent as cancer and growing faster, these diseases remain invisible: under-recognized, under-researched and under-served. In particular, multiple medical specialty silos within
A continuation of Part 1. One of our B2B thought leadership interviews with digital health entrepreneurs working to improve the care of chronic conditions. We care particularly about chronic immunoinflammatory disorders (CIIDs), e.g., autoimmune and autoinflammatory diseases. This continues our interview with the CEO of Oshi Health, Sam Holliday. Oshi
First 2021 post in our series of B2B thought leadership interviews with visionary digital health entrepreneurs working to improve care of chronic conditions. In keeping with our mission, we particularly care about chronic immunoinflammatory disorders (CIIDs), e.g., autoimmune and autoinflammatory diseases. Bonnie and Ellen were happy to finally interview digital
The COVID-19 pandemic and healthcare systems’ responses to it have been the biggest disruptors in digital health’s 30-year history. We hope this will be the biggest disruptor for a few decades to come! Therefore, this is a unique moment of opportunity for digital health. Especially for digital and virtual-first chronic
On GI practice, beta risk, digital health, VBP and chronic care Another in our new series of B2B thought leadership interviews with visionary entrepreneurs applying digital tools to improve care of chronic immunoinflammatory disorders (CID), including autoimmune and autoinflammatory diseases. We were delighted to speak with Dr Lawrence R. Kosinski,